XBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.
Follow XBIT
XBiotech Inc. (XBIT) EV/Sales
As of 16 October 2026, XBiotech Inc. (XBIT) trades at a EV/Sales of −8.6×. Over the past ten years it has ranged from −29.8× (April 2023) to 27.4× (April 2024); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −28.6× | — |
| FY2021 | 5.3× | (4.92%) |
| FY2020 | 5.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −28.6× | — |
| Sep 2022 | −13.4× | — |
| Jun 2022 | −4.9× | — |
| Mar 2022 | 2.2× | (58.08%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XBIT XBiotech Inc. | −8.6× |
| FBIO Fortress Biotech, Inc. compare | −1.4× |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 0.2× |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| VRCA Verrica Pharmaceuticals Inc. compare | 2.6× |
| HYFT MindWalk Holdings Corp. compare | 5.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)